EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort

Yifei Chen, Ruyan Zhang, Ran Ran, Yaxin Liu iD, Jiayang Zhang, Ying Yan, Bin Shao, Xu Liang, Hanfang Jiang, Lijun Di, Guohong Song, Huiping Li iD

Current Oncology · 18.08.2026 · 33 (8) · 487

DOI: 10.3390/curroncol33080487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 18.08.2026. Verfasst von Yifei Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer …. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University Cancer Hospital, Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We retrospectively analyzed consecutive patients with HER2-positive metastatic breast cancer who received T-DXd at a single Chinese cancer center between March 2023 and March 2026. Progression-free survival (PFS), overall survival (OS), systemic and intracranial response, safety, prognostic factors, and exploratory subsequent treatment strategies were assessed. Among 173 eligible patients, 80.3% had received prior HER2-directed TKIs and 41.6% had CNS metastases. After a median follow-up of 14.3 months, median PFS and OS were 14.1 and 31.1 months, respectively. The objective response rate was 54.5% among 154 patients with measurable systemic disease, while the CNS objective response rate was 46.3% among 67 patients with measurable CNS lesions. Among patients with measurable CNS lesions, the CNS-ORR was comparable between patients with and without peri-T-DXd local treatment (53.8% vs. 44.4%, p = 0.21). Greater prior treatment exposure was associated with shorter PFS, whereas HER2 IHC 3+ disease was independently associated with longer OS and showed a trend toward improved PFS compared with HER2 IHC 2+/FISH-positive disease. Interstitial lung disease occurred in 13 patients (7.5%), all grade 1–2. Among 148 patients included in the maintenance analysis, 23 switched to alternative maintenance regimens after initial benefit from T-DXd. In an exploratory analysis, no statistically significant differences in PFS or OS were observed between patients who continued T-DXd and those who switched to maintenance therapy. However, these findings require cautious interpretation because of immortal-time bias, selection bias, and limited sample size. T-DXd demonstrated clinically meaningful systemic and intracranial activity with manageable toxicity in this heavily pretreated real-world cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedHumansFemaleRetrospective StudiesMiddle AgedAdultAgedTreatment OutcomeNeoplasm MetastasisChinaEast Asian PeopleCamptothecinImmunoconjugates

Stichwörter der Autor:innen

HER2-positive breast cancerTKI pretreatedmaintenance therapymetastatic breast cancerreal-world studytrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine Kinasestrastuzumab deruxtecanERBB2 protein, humanAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugates

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

ORCID-Profile: Yaxin Liu, Huiping Li

Förderung

  • Peking University Cancer Hospital
  • Science Foundation of Peking University Cancer Hospital

Zitieren

APA

Chen, Y., Zhang, R., Ran, R., Liu, Y., Zhang, J., Yan, Y., Shao, B., Liang, X., Jiang, H., Di, L., Song, G., & Li, H. (2026). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort. Current Oncology, 33(8), 487. https://doi.org/10.3390/curroncol33080487

Vancouver

Chen Y, Zhang R, Ran R, Liu Y, Zhang J, Yan Y, et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort. Current Oncology. 2026;33(8):487. doi:10.3390/curroncol33080487

BibTeX
@article{Chen2026,
  author = {Chen, Yifei and Zhang, Ruyan and Ran, Ran and Liu, Yaxin and Zhang, Jiayang and Yan, Ying and Shao, Bin and Liang, Xu and Jiang, Hanfang and Di, Lijun and Song, Guohong and Li, Huiping},
  title = {Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {487},
  doi = {10.3390/curroncol33080487}
}
Kostenlos starten →